Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19
CALAVI did not meet the primary endpoint of increasing the proportion of patients who remained alive and free of respiratory failure

The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalized with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. The addition of Calquence to best supportive care (BSC) did not increase the proportion of patients who remained alive and free of respiratory failure. No new safety signal for Calquence was observed in the trials.

José Baselga, Executive Vice President, Oncology R&D, said: “Since the beginning of the year, AstraZeneca has been committed to doing everything we can to respond to COVID-19, including investigating existing medicines as potential treatments. The CALAVI trials were launched based on preclinical and early clinical evidence that Calquence could decrease the hyperinflammatory immune response and improve clinical outcomes in patients hospitalized with respiratory symptoms of COVID-19.1 While the CALAVI results are disappointing, we remain committed to advancing science that helps patients during this unprecedented global pandemic, including clinical trials for the AstraZeneca Oxford coronavirus vaccine and our long-acting antibody combination.”

The CALAVI program comprised two Phase II trials investigating acalabrutinib plus BSC versus BSC alone in hospitalized patients with COVID-19 disease.

The safety and tolerability profiles for Calquence in the CALAVI Phase II trials were consistent with previous trials. The data will be presented in due course.

Results from the CALAVI Phase II trials do not impact approved indications or pending approvals for Calquence in patients with blood cancers.

Tags : #LatestPharmaNewsNov12 #LatestAstrazenecaNewsNov12 #TreatmentforCovid19

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Patient Safety Is a Business Priority for Indian HospitalsNovember 10, 2026
Reducing ED Wait Times Through Smarter Hospital DesignNovember 10, 2026
Maternal Mental Health: Integrating Emotional Wellbeing Into Postnatal CareNovember 10, 2026
Occupational Health for Healthcare Workers: Preventing Musculoskeletal StrainNovember 10, 2026
Sleep Health in India: Recognising the Public Health Impact of Sleep DisordersNovember 06, 2026
Childhood Hearing Screening: Linking Early Detection With Timely SupportNovember 06, 2026
Low-Dose Imaging in India: Accuracy Meets SafetyNovember 06, 2026
Synthetic Health Data: Powering the Future of Medical AINovember 06, 2026
AI and Clinical Trials: How ML Is Changing Patient RecruitmentNovember 05, 2026
Photon-Counting CT: What Indian Hospitals Need to KnowNovember 05, 2026
Rare Diseases in India: Navigating Diagnosis, Support and Long-Term CareNovember 05, 2026
Oral Health and Systemic Health: The Case for Routine Dental IntegrationNovember 05, 2026
KIMS Hospitals Takes Another Major Step Forward in Cancer Care with Advanced TrueBeam TechnologyNovember 04, 2026
SRM Medical College Hospital and Research Centre Hosts National Conference on Translational Regenerative Biology and Bioengineering – TRBB 2026November 04, 2026
15-Month-Old Russian Baby Avoids Lung Transplant Following Treatment at MGM HealthcareNovember 04, 2026
Why Diabetes Care Must Go Beyond Blood Sugar ControlNovember 04, 2026
Sri Sathya Sai Heart Hospital Successfully Organises Free Heart Camp, Screening for 550 Patients in Dehradun, UttarakhandNovember 04, 2026
Expert Quote | Rising Air Pollution in Delhi | Agilus DiagnosticsNovember 04, 2026
Healthcare AI Safety Officers: India's New Leadership NeedNovember 04, 2026
Next-Generation Medical Imaging: Beyond Traditional ScansNovember 04, 2026